Kolkata :Prevalence of type 2 diabetes mellitus (T2DM) is increasing globally and has reached epidemic proportions in many countries especially India. Kolkata’s leading endocrinologist Dr. Sudip Chatterjee addressed a media gathering to highlight an increased prevalence of cardiovascular disease (CVD) and kidney disease in people with type 2 diabetes and the need for a paradigm shift in effective diabetes management. The findings of the latest EMPA-REG study suggests a significant reduction in the risk of progressive kidney disease in adults with type 2 diabetes with established CVD.
Kidney disease affects about 50% of people with type 2 diabetes where as people with diabetes are two to four times more likely to develop CVD than people without diabetes due to factors such as such as high blood sugar, high blood pressure and obesity.2, Error! Reference source not found.
Dr. Sudip Chatterjee, MD, MNAMS (Endocrinology), Honorary Professor, Vivekanand Institute of Medical Sciences and Honorary Secretary, Park Clinic, Kolkata said, “Uncontrolled diabetes can lead to serious complications such as CVD, kidney problems or other serious health complications. The risk for cardiovascular events increases in patients with type 2 diabetes as they age. Cardiovascular disease is the leading cause of death in 80% patients with type 2 diabetes. In our city, more than 20% people with type 2 diabetes are also at risk of developing kidney disease which can lead to kidney failure and eventually need dialysis. Proteinuria (presence of protein in the urine) confers a 4 times greater risk of ischemic heart disease as compared to normal individuals.”
Diabetes is known to be the number one reason for people requiring dialysis treatment. With the rapidly growing trend of diabetes in India which is fast gaining the reputation of a potential epidemic, there is a need for new treatments that may have the potential to help address this crucial medical need are necessary.
EMPA REG OUTCOME was a recently concluded global trial of more than 7,000 patients from 42 countries which included close to 163 enrolled from Indian patients with type 2 diabetes and established CVD, Dr. Chatterjee said,“As per the results of the EMPA-REG OUTCOME® trial, empagliflozin reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in people with type 2 diabetes with established cardiovascular disease. Empagliflozin reduces the risk of cardiovascular death and hospitalization for heart failure in people with type 2 diabetes. This is the new standard of care in effective diabetes management with a holistic approach towards patient care.”